Dulac Edward J III — SEC Form 4 filings
SEC reporting owner CIK 1821530. 13 Form 4 filings on record with FilingPulse; latest filed 2026-07-24.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2023-12-19 to 2026-07-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 9 filings — 44,720 shares, $422,287 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
- Largest priced transaction: sale of 7,462 shares @ $14.02 ($104,617) in Intellia Therapeutics, Inc., filed 2025-07-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | EVP, Chief Financial Officer | 7 | — | 4 legs · 26,629 sh · $338,803 | 6 |
| FATE THERAPEUTICS INC (FATE) | Chief Financial Officer | 6 | — | 5 legs · 18,091 sh · $83,484 | 1 |
Form 4 filings — Dulac Edward J III
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-24 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 8,111 @ $11.25 | EDGAR |
| 2026-07-06 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 4,677 @ $18 | EDGAR |
| 2026-03-03 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 61,280 @ $0 · Grant/award (A): 87,543 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 6,379 @ $9.21 | EDGAR |
| 2025-07-25 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 7,462 @ $14.02 | EDGAR |
| 2025-03-04 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 47,200 @ $0 · Grant/award (A): 67,429 (derivative) @ $0 | EDGAR |
| 2024-07-24 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 66,324 @ $0 · Grant/award (A): 96,219 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | FATE THERAPEUTICS INC (FATE) | Sale (S): 2,447 @ $7.77 | EDGAR |
| 2024-02-02 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 425,000 (derivative) @ $0 | EDGAR |
| 2024-01-30 | 4 | FATE THERAPEUTICS INC (FATE) | Sale (S): 1,849 @ $5 | EDGAR |
| 2024-01-10 | 4 | FATE THERAPEUTICS INC (FATE) | Sale (S): 7,028 @ $4.37 | EDGAR |
| 2024-01-03 | 4 | FATE THERAPEUTICS INC (FATE) | Sale (S): 5,182 @ $3.66 | EDGAR |
| 2023-12-19 | 4 | FATE THERAPEUTICS INC (FATE) | Sale (S): 1,585 @ $3.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2023-12-15 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1821530 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →